These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Targeting the proapoptotic factor Bcl-2 in non-Hodgkin's lymphoma. Klasa RJ Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):25-31. PubMed ID: 15651174 [TBL] [Abstract][Full Text] [Related]
4. [Proapoptotic therapy with oblimersen (bcl-2 antisense oligonucleotide)--review of preclinical and clinical results]. Büchele T Onkologie; 2003 Dec; 26 Suppl 7():60-9. PubMed ID: 14716145 [TBL] [Abstract][Full Text] [Related]
5. Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts. Smith MR; Jin F; Joshi I Mol Cancer Ther; 2004 Dec; 3(12):1693-9. PubMed ID: 15634664 [TBL] [Abstract][Full Text] [Related]
6. Potential therapeutic applications of oblimersen in CLL. Koziner B Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):32-8. PubMed ID: 15651175 [TBL] [Abstract][Full Text] [Related]
9. Bcl-2 antisense oligonucleotides are effective against systemic but not central nervous system disease in severe combined immunodeficient mice bearing human t(14;18) follicular lymphoma. Mohammad R; Abubakr Y; Dan M; Aboukameel A; Chow C; Mohamed A; Hamdy N; Al-Katib A Clin Cancer Res; 2002 Apr; 8(4):1277-83. PubMed ID: 11948143 [TBL] [Abstract][Full Text] [Related]
11. Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab. Ramanarayanan J; Hernandez-Ilizaliturri FJ; Chanan-Khan A; Czuczman MS Br J Haematol; 2004 Dec; 127(5):519-30. PubMed ID: 15566355 [TBL] [Abstract][Full Text] [Related]
12. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739 [TBL] [Abstract][Full Text] [Related]
13. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development. Holmlund JT; Monia BP; Kwoh TJ; Dorr FA Curr Opin Mol Ther; 1999 Jun; 1(3):372-85. PubMed ID: 11713802 [TBL] [Abstract][Full Text] [Related]
14. Anti-Bcl2 therapy in chronic myelogenous leukemia. Smith S Leuk Lymphoma; 2008 Jul; 49(7):1232-3. PubMed ID: 18604712 [No Abstract] [Full Text] [Related]
15. Bcl-2 antisense in the treatment of human malignancies: a delusion in targeted therapy. Gjertsen BT; Bredholt T; Anensen N; Vintermyr OK Curr Pharm Biotechnol; 2007 Dec; 8(6):373-81. PubMed ID: 18289046 [TBL] [Abstract][Full Text] [Related]
16. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles. Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711 [TBL] [Abstract][Full Text] [Related]
17. Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein. van de Donk NW; Kamphuis MM; van Dijk M; Borst HP; Bloem AC; Lokhorst HM Leukemia; 2003 Jan; 17(1):211-9. PubMed ID: 12529680 [TBL] [Abstract][Full Text] [Related]
18. Targeting Bcl-2 protein expression in solid tumors and hematologic malignancies with antisense oligonucleotides. Tolcher AW Clin Adv Hematol Oncol; 2005 Aug; 3(8):635-42, 662. PubMed ID: 16167050 [TBL] [Abstract][Full Text] [Related]